CORDIS · 101244235 · HORIZON
GlioLight Novel peptidomimetics for inhibition of MDM2 in glioblastoma
Coordinator: RUDER BOSKOVIC INSTITUTE (HR)
Mouse double minute 2 homolog (MDM2) is a primary antagonist of p53 tumour suppressor, and MDM2 inhibition represents an attractive way to restore p53 function. Peptidomimetics which are based on p53 sequence-derived structure, are one of the most promising tools for mimicking MDM2/p53 interaction. Varying structure of peptidomimetics gives opportunity to measure effect of fine structure changes on inhibition process. Linking peptidomimetics with fluorophores represents an attractive way to spatially track inhibition process. In this project we aim to synthesize novel fluorophore-peptidomimet…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
The project runs over approximately 3.7 years from 2025-09-01 to 2029-04-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from HR
see all →- MARBLE — Centre of Excellence in Maritime Robotics and Technologies for Sustainable Blue Economy101136349 · HORIZON · €15.0M
- ANEUPLOIDY — Molecular origins of aneuploidies in healthy and diseased human tissues855158 · H2020 · €10.0M
- InnoThyroGen — Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence101187880 · HORIZON · €4.9M
- INNOMOL — Enhancement of the Innovation Potential in SEE through new Molecular Solutions in Research and Development316289 · FP7 · €4.7M
- GLOWBRAIN — Combining Stem Cells and Biomaterials for Brain Repair - Unlocking the Potential of the Existing Brain Research through Innovative In Vivo Molecular Imaging316120 · FP7 · €3.8M
- ACROSS — Centre of Research Excellence for Advanced Cooperative Systems285939 · FP7 · €3.4M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-TMA-MSCA-PF-EF funding scheme.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-WIDERA-2024-TALENTS-02.
- Who coordinates the project?
- The project is coordinated by RUDER BOSKOVIC INSTITUTE (HR).
- What is the project timeline?
- The project runs from 2025-09-01 to 2029-04-30 — approximately 3.7 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101244235.